PT-141 Melanocortin Receptor Research

PT-141, known in scientific literature as bremelanotide, is a synthetic cyclic heptapeptide with the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of approximately 1025 Da. It retains the His-Phe-Arg-Trp core sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), which represents the minimal pharmacophore required for melanocortin receptor binding. The cyclic conformation confers resistance to enzymatic degradation and contributes to its binding profile at melanocortin receptor subtypes.

The peptide emerged from melanocortin pharmacology programs originating at the University of Arizona and was subsequently developed as a research analog optimized for central melanocortin receptor activity. Because it shares the alpha-MSH core pharmacophore, PT-141 sits within the same peptide family as other melanocortin-derived research peptides, including the C-terminal tripeptide discussed in our KPV peptide anti-inflammatory research overview, though the two engage the melanocortin system through markedly different mechanisms.

The melanocortin system comprises five G-protein-coupled receptor subtypes, MC1R through MC5R, each with distinct tissue distribution and function. MC1R is associated with pigmentation in melanocytes, MC2R with adrenal steroidogenesis, and MC5R with exocrine gland function. The MC3R and MC4R subtypes are expressed predominantly in the central nervous system, where they participate in the regulation of energy balance, autonomic tone, and sexual function.

PT-141 acts as an agonist across several melanocortin receptors, with research characterizing meaningful activity at MC3R and MC4R and comparatively lower activity at MC1R. This relative selectivity away from MC1R is of research interest because MC1R activation drives melanogenesis, and reduced MC1R engagement corresponds to a distinct profile relative to less selective melanocortin agonists. Receptor binding couples to adenylyl cyclase through stimulatory G proteins, elevating intracellular cyclic AMP in target neurons.

A foundational study by Van der Ploeg and colleagues, published in PNAS (2002), used combined genetic, pharmacological, and anatomical approaches to establish the melanocortin 4 receptor as a mediator of erectile function and sexual behavior in animal models. The research reported that a highly selective non-peptide MC4R agonist augmented erectile activity initiated by cavernous nerve stimulation in wild-type mice but not in Mc4r-null mice, and that copulatory behavior was enhanced by a selective MC4R agonist while diminished in mice lacking the receptor. The study also documented MC4R expression across spinal cord, hypothalamus, brainstem, and pelvic ganglion tissue.

Complementary work by Martin and colleagues (2002) demonstrated in an ex copula rat model that melanocortin-induced erectile activity is mediated by MC4 receptors, helping to resolve which subtype carries the pro-erectile signal given that endogenous melanocortin peptides do not discriminate between receptors.

PT-141-specific pharmacology was characterized by Molinoff and colleagues (2003), who reported that systemic administration of the peptide to rats and nonhuman primates was associated with penile erections and activated hypothalamic neurons, evidenced by increased c-Fos immunoreactivity. The same research noted that neurons in this central region take up pseudorabies virus injected into the corpus cavernosum, anatomical evidence linking the activated hypothalamic circuits to peripheral effector tissue. This central mode of action distinguishes melanocortin agonists from peripherally acting vasodilator compounds studied in the same domain.

More recent circuit-level research by Semple and colleagues (2017) narrowed the relevant neural substrate, reporting that MC4R expression restricted to single-minded homolog 1 (Sim1) neurons was sufficient to support MC4R-mediated male sexual function in a conditional mouse model. This work advanced the field from receptor-level to circuit-level resolution of the melanocortin sexual-function pathway.

While MC4R has emerged as the principal effector in melanocortin-induced erectile research, the relative contribution of MC3R remains an active question. A review of melanocortin receptors and melanotropic peptides noted conflicting data across studies, with some laboratories suggesting that antagonism of forebrain MC3R may actually enhance melanocortin-induced erections. Because PT-141 engages both subtypes, it has served as a pharmacological tool for probing this distinction rather than a purely MC4R-selective probe.

A broader review by Shadiack and colleagues surveyed melanocortinergic agents in sexual-function research, situating PT-141 alongside related compounds such as MT-II and THIQ and attributing their shared erectogenic properties to central melanocortin receptor binding, particularly within the hypothalamus. Together these reviews frame PT-141 as a central-acting melanocortin agonist whose subtype pharmacology continues to be refined.

Preclinical literature has examined PT-141 across several interconnected research contexts: